Edition:
United States

Aeterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

2.87USD
21 Jul 2017
Change (% chg)

$0.07 (+2.50%)
Prev Close
$2.80
Open
$3.20
Day's High
$3.22
Day's Low
$2.65
Volume
17,686,693
Avg. Vol
1,762,790
52-wk High
$5.59
52-wk Low
$0.78

AEZS.O

Chart for AEZS.O

About

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $39.63
Shares Outstanding(Mil.): 14.33
Dividend: --
Yield (%): --

Financials

  AEZS.O Industry Sector
P/E (TTM): -- 215.12 15.95
EPS (TTM): -2.34 -- --
ROI: -80.14 -7.79 -8.24
ROE: -234.78 -9.19 -7.87

BRIEF-Aeterna Zentaris says ‍strategic review committee will be chaired by Carolyn Egbert, and includes Michael Cardiff​

* Aeterna Zentaris forms strategic review committee and appoints Michael Ward as CEO

Jul 20 2017

BRIEF-NDA for Aeterna Zentaris' Macrilen granted PDUFA date

* NDA for Macrilen for the evaluation of growth hormone deficiency in adults granted December 30, 2017 PDUFA date

Jul 18 2017

BRIEF-Aeterna Zentaris resubmits NDA for Macrilen for the evaluation of growth hormone deficiency in adults

* Aeterna Zentaris resubmits NDA for Macrilen™ for the evaluation of growth hormone deficiency in adults

Jun 30 2017

BRIEF-Aeterna Zentaris says ZoptEC Phase 3 clinical study of Zoptrex did not achieve primary endpoint

* Aeterna Zentaris announces that ZoptEC Phase 3 clinical study of Zoptrex did not achieve its primary endpoint

May 01 2017

BRIEF-Aeterna Zentaris intends to file NDA with respect to Macrilen in Q3

* Aeterna Zentaris intends to file NDA with respect to Macrilen™ in third quarter of 2017 Source text for Eikon: Further company coverage:

Mar 30 2017

BRIEF-Aeterna Zentaris files for common shares stock shelf offering of up to $50 mln

* Aeterna Zentaris Inc- files for common shares stock shelf offering of up to $50 million - sec filing Source text (http://bit.ly/2mMXM6t) Further company coverage:

Mar 21 2017

BRIEF-Aeterna Zentaris qtrly loss per share $0.71

* Aeterna Zentaris reports fourth quarter and full-year 2016 financial and operating results

Mar 15 2017

BRIEF-Aeterna Zentaris announces EMA pediatric committee agreement

* Aeterna Zentaris announces EMA pediatric committee agreement on the pediatric investigation plan for macrilen(TM)

Mar 07 2017

Earnings vs. Estimates